In a subgroup analysis of the VESALIUS-CV trial found that Evolocumab reduces the risk of a first major cardiovascular event in high-risk patients with diabetes
A recent study suggests that measures of central obesity, such as waist circumference and waist-to-height ratio, may be more useful than BMI in identifying future heart failure risk.